6,790 Shares in Eli Lilly and Company $LLY Purchased by First Nebraska Trust Co

First Nebraska Trust Co acquired a new position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 6,790 shares of the company's stock, valued at approximately $7,856,000.

Other hedge funds also recently modified their holdings of the company. Stiles Financial Services Inc raised its holdings in shares of Eli Lilly and Company by 3.0% during the third quarter. Stiles Financial Services Inc now owns 1,865 shares of the company's stock valued at $2,158,000 after purchasing an additional 54 shares during the period. Factory Mutual Insurance Co. boosted its position in shares of Eli Lilly and Company by 5.0% during the 3rd quarter. Factory Mutual Insurance Co. now owns 85,031 shares of the company's stock worth $98,388,000 after purchasing an additional 4,031 shares in the last quarter. Tucker Asset Management LLC grew its stake in shares of Eli Lilly and Company by 115.1% in the 3rd quarter. Tucker Asset Management LLC now owns 542 shares of the company's stock valued at $628,000 after buying an additional 290 shares during the period. Bauman Advisory Group LLC acquired a new stake in shares of Eli Lilly and Company in the 3rd quarter valued at about $225,000. Finally, Eads & Heald Wealth Management grew its stake in shares of Eli Lilly and Company by 0.5% in the 3rd quarter. Eads & Heald Wealth Management now owns 1,469 shares of the company's stock valued at $1,700,000 after buying an additional 8 shares during the period. Institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Trading Down 0.2%

NYSE LLY opened at $1,408.68 on Wednesday. The stock has a market capitalization of $1.33 trillion, a price-to-earnings ratio of 45.72, a PEG ratio of 1.77 and a beta of 0.40. Eli Lilly and Company has a one year low of $850.51 and a one year high of $1,449.68. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.39 and a quick ratio of 1.00. The business's fifty day moving average is $1,204.03 and its 200-day moving average is $1,095.92.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings results on Thursday, October 29th. The company reported $7.48 earnings per share for the quarter, topping analysts' consensus estimates of $5.71 by $1.77. The company had revenue of $24.40 billion for the quarter, compared to the consensus estimate of $22.58 billion. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. The firm's quarterly revenue was up 38.6% on a year-over-year basis. During the same period in the previous year, the firm earned $7.02 EPS. Equities research analysts predict that Eli Lilly and Company will post 35.61 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Shareholders of record on Friday, November 13th will be given a $1.73 dividend. The ex-dividend date of this dividend is Friday, November 13th. This represents a $6.92 annualized dividend and a yield of 0.5%. Eli Lilly and Company's payout ratio is currently 22.46%.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly’s third-quarter revenue of $24.4 billion and EPS of $7.48 topped estimates, while revenue rose 38.6% year over year. The company raised its 2026 revenue outlook to $91 billion–$92 billion, reinforcing the demand-driven growth case. Raised Guidance Altering The Investment Case For Eli Lilly Stock?
• Positive Sentiment: Mounjaro and Zepbound remain key growth engines. Retatrutide also showed encouraging Phase 3 results versus Ozempic 2 mg in a diabetes trial, strengthening Lilly’s competitive position and future pipeline prospects. Eli Lilly Just Gained 22% in a Month
• Positive Sentiment: Cantor Fitzgerald raised its price target to $1,600 from $1,440 and maintained an “overweight” rating, reflecting optimism about the company’s outlook.
• Neutral Sentiment: EVP Anat Hakim sold 5,000 shares under a pre-arranged Rule 10b5-1 plan. The sale reduced her direct holdings by 54.72%, though planned insider transactions may carry less information than discretionary sales. SEC Form 4 filing
• Negative Sentiment: Some commentary warns that expectations may be ahead of sustainable growth: revenue growth could moderate, realized drug prices are reportedly falling, and some recent revenue contributions may not recur. A high valuation makes the shares more sensitive to any slowdown. Eli Lilly: Priced For Acceleration, Reporting Deceleration
• Negative Sentiment: Pipeline setbacks and dropped drug candidates outside the GLP-1 franchise raise questions about whether Lilly can broaden growth beyond its current blockbuster products. Lilly’s R&D whirlwind

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, EVP Anat Hakim sold 5,000 shares of the business's stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $1,402.52, for a total value of $7,012,600.00. Following the transaction, the executive vice president directly owned 4,137 shares in the company, valued at $5,802,225.24. The trade was a 54.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the transaction, the executive vice president directly owned 54,147 shares of the company's stock, valued at $63,628,139.70. This represents a 10.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 18,500 shares of company stock worth $22,970,770 over the last three months. 0.14% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

LLY has been the subject of a number of research analyst reports. Wells Fargo & Company boosted their target price on Eli Lilly and Company from $1,330.00 to $1,500.00 and gave the company an "overweight" rating in a research report on Friday. The Goldman Sachs Group reiterated a "buy" rating and issued a $1,413.00 price target on shares of Eli Lilly and Company in a report on Tuesday, October 20th. Scotiabank raised their price objective on Eli Lilly and Company from $1,300.00 to $1,605.00 and gave the company a "sector outperform" rating in a research note on Friday, October 30th. UBS Group raised their price objective on Eli Lilly and Company from $1,425.00 to $1,625.00 and gave the company a "buy" rating in a research note on Friday. Finally, Guggenheim boosted their price objective on Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the company a "buy" rating in a report on Friday, September 18th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Eli Lilly and Company currently has a consensus rating of "Moderate Buy" and an average price target of $1,404.14.

About Eli Lilly and Company

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company's portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.